Related Experiment Video
Updated: Sep 9, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
CAR-T cell therapy for glioblastoma: advances, challenges, and future directions
Wojciech Czyżewski1,2, Klaudia Kus-Budzynska3, Jan Sobstyl4
1Department of Neurosurgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Background:
Chimeric antigen receptor T (CAR-T) therapy for glioblastoma involves critically evaluating progress, effectiveness, and challenges. By examining current research, clinical trials, and emerging trends, the analysis highlights clinical outcomes and biological insights that demonstrate the therapeutic potential of CAR-T cells, along with technological innovations aimed at enhancing their efficacy and safety. However, significant obstacles such as overcoming the blood-brain barrier and managing severe side effects like cytokine release syndrome remain.
Methods:
A systematic search using PubMed, Scopus, Web of Science, and Google Scholar from 2010 to 2024 has been conducted. Search terms included "CAR-T," "glioblastoma," "immunotherapy," and "clinical trials." Inclusion criteria were English-language studies focusing on CAR-T applications in glioblastoma. Exclusion criteria included non-peer-reviewed articles and preclinical-only studies.
Findings:
The findings suggest promising prospects for integrating CAR-T cell therapy into existing glioblastoma treatment paradigms, emphasizing the need for continued research and innovation in genetic engineering and combination therapies to fully realize the potential of CAR-T cells in transforming glioblastoma treatment.
Conclusions:
CAR-T cell therapy offers groundbreaking potential in transforming glioblastoma treatment by harnessing the immune system to target and destroy cancer cells.
Insights
Chimeric antigen receptor T (CAR-T) therapy shows promise for glioblastoma treatment by using the immune system to fight cancer. Continued research is vital to overcome challenges and enhance CAR-T cell efficacy and safety.
Area of Science:
- Oncology
- Immunotherapy
- Neuroscience
Background:
- Chimeric antigen receptor T (CAR-T) therapy is being evaluated for glioblastoma treatment.
- Current research and clinical trials highlight the therapeutic potential and challenges of CAR-T cells.
- Key obstacles include the blood-brain barrier and managing side effects like cytokine release syndrome.
Purpose of the Study:
- To critically evaluate the progress, effectiveness, and challenges of CAR-T therapy for glioblastoma.
- To examine current research, clinical trials, and emerging trends in CAR-T applications for glioblastoma.
- To identify technological innovations for enhancing CAR-T cell efficacy and safety.
Main Methods:
- A systematic literature search was conducted from 2010 to 2024.
- Databases searched included PubMed, Scopus, Web of Science, and Google Scholar.
- Search terms focused on CAR-T, glioblastoma, immunotherapy, and clinical trials, with specific inclusion/exclusion criteria.
Main Results:
- CAR-T cell therapy demonstrates significant therapeutic potential for glioblastoma.
- Clinical outcomes and biological insights support the use of CAR-T cells.
- Technological innovations are emerging to improve CAR-T cell efficacy and safety.
Conclusions:
- CAR-T cell therapy holds groundbreaking potential for glioblastoma treatment.
- Integration into existing treatment paradigms is promising.
- Continued research in genetic engineering and combination therapies is essential to maximize CAR-T cell potential.
More Related Videos
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
